Last year, British Columbia became the first province to introduce a mandatory biosimilar switching program for non-medical reasons.
access to new medicine
The biopharmaceutical industry is uniquely prepared to combat COVID-19.
Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.
Developing and testing new drugs costs a lot of money.
Nobel laureate Paul Romer’s key new insight was that human capital can produce ideas.
Profit incentivizes innovation and helps fund research and development.